Trends In Angiogenesis Research
Download Trends In Angiogenesis Research full books in PDF, epub, and Kindle. Read online free Trends In Angiogenesis Research ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
| Author | : Roberta V. Zubar |
| Publisher | : Nova Publishers |
| Total Pages | : 266 |
| Release | : 2005 |
| Genre | : Medical |
| ISBN | : 9781594544521 |
Angiogenesis -- the growth of new blood vessels -- is an important natural process occurring in the body, both for health and as related to disease. Angiogenesis occurs in the healthy body to help heal wounds and to help restore blood flow to tissues after injury or insult. In females, angiogenesis also occurs during the monthly reproductive cycle (to rebuild the uterus lining, to mature the egg during ovulation) and during pregnancy (to build the placenta, the circulation between mother and foetus). The healthy body controls angiogenesis through a series of "on" and "off" switches. The main "on" switches are known as angiogenesis-stimulating growth factors. The main "off switches" are known as angiogenesis inhibitors. When angiogenic growth factors are produced in excess of angiogenesis inhibitors the balance is tipped in favour of blood vessel growth. When inhibitors are present in excess of stimulators, angiogenesis is stopped. The normal, healthy body maintains a perfect balance of angiogenesis modulators. In general, angiogenesis is "turned off" by the production of more inhibitors than stimulators. Tumour angiogenesis is the proliferation of a network of blood vessels that penetrates into cancerous growths, supplying nutrients and oxygen and removing waste products. Tumour angiogenesis actually starts with cancerous tumour cells releasing molecules that send signals to surrounding normal host tissue. This signalling activates certain genes in the host tissue that, in turn, cause proteins to encourage growth of new blood vessels. This new book examines its angiogenesis within the context of theory and its applications to cancer treatment.
| Author | : William D. Figg |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 592 |
| Release | : 2008-05-24 |
| Genre | : Medical |
| ISBN | : 0387715185 |
Dr. Judah Folkman is considered the "father of angiogenesis." Because of Folkman's discovery and research, the possibilities of angiogenic therapy have broadened beyond cancer to many noncancerous diseases. Angiogenesis: An Integrative Approach from Science to Medicine is a comprehensive, concise summary of tumor angiogenesis. It is an up-to-date and authoritative reference for the angiogenesis field as it relates to oncology. This book represents the first collection in a volume of which Folkman is co-editor. Folkman has authored nearly 400 original papers and more than 100 book chapters.
| Author | : Domenico Ribatti |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 126 |
| Release | : 2008-12-16 |
| Genre | : Medical |
| ISBN | : 1402095635 |
In 1971, J. Folkman published in the “New England Journal of Medicine” a hypothesis that tumor growth is angiogenesis-dependent. Folkman introduced the concept that tumors probably secrete diffusible molecules that could stimulate the growth of new blood vessels toward the tumor and that the resulting tumor neovascularization could conceivably be prevented or interrupted by angiogenesis inhibitors. Solid and haematological tumors consist of an avascular and a subsequent vascular phase. Assuming that this depends on the release of angiogenic factors, acquisition of angiogenic capability can be seen as an expression of progression from neoplastic transformation to tumor growth and metastasis. Beginning in the 1980’s, the biopharmaceutical industry began exploiting the field of antiangiogenesis for creating new therapeutic compounds for modulating new blood vessels in tumor growth. In 2004, Avastin (Bevacizumab), a humanized anti-VEGF monoclonal antibody, was the first angiogenesis inhibitor approved by the Food and Drug Administration for the treatment of colorectal cancer. At present, it has been estimated that over 20,000 cancer patients worldwide have received experimental form of antiangiogenic therapy. This book offers a historical account of the relevant literature. It also emphasizes the crucial and paradigmatic role of angiogenesis as a biological process and the significance of antiangiogenic approach for the treatment of tumors.
| Author | : Reza Forough |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 226 |
| Release | : 2006-01-11 |
| Genre | : Medical |
| ISBN | : 9781402043260 |
New Frontiers in Angiogenesis is a fresh and unconventional look at the field of angiogenesis. It focuses on provocative and cutting-edge topics in the field of angiogenesis. Each chapter will take the reader along on a journey into uncharted territories of angiogenesis. The volume starts with a comprehensive overview of the field and continues with topics that have been minimally explored. The topics deal with dynamics of vasculogenesis using imaging techniques, bone marrow-derived endothelial cell precursors as potential therapeutic tools, regulation of post-angiogenic vessel regression, vascular mimicry, design and construction of artificial vessels, bioengineering of angiogenesis, and lymphangiogenesis recapitulating angiogenesis in health and disease states. Each chapter is written by leading experts of the subjects. It is hoped that this volume will challenge all of us interested in the field of angiogenesis and cardiovascular biology, in particular those in academia and industries, to think "outside the box" and explore angiogenesis from a fresh angle. It is hoped that New Frontiers in Angiogenesis is thought provoking and serve as a road map for discovering new findings to help betterments of human health.
| Author | : Cynthia A Reinhart-King |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 280 |
| Release | : 2012-09-14 |
| Genre | : Technology & Engineering |
| ISBN | : 3642308562 |
This volume describes and discusses recent advances in angiogenesis research. The chapters are organized to address all biological length scales of angiogenesis: molecular, cellular and tissue in both in vivo and in vitro settings. Specific emphasis is given to novel methodologies and biomaterials that have been developed and applied to angiogenesis research. Angiogenesis experts from diverse fields including engineering, cell and developmental biology, chemistry and physics will be invited to contribute chapters which focus on the mechanical and chemical signals which affect and promote angiogenesis.
| Author | : Jianyuan Chai |
| Publisher | : BoD – Books on Demand |
| Total Pages | : 304 |
| Release | : 2013-02-06 |
| Genre | : Medical |
| ISBN | : 9535109634 |
Angiogenesis is an extension process of the cardiovascular network within human body. It is usually triggered by the demand of oxygen and nutrients from the fast growing tissue and uncontrollably dividing cells, as seen during wound healing and tumor progression. This book focuses on tumor angiogenesis and includes 8 chapters written by highly experienced scholars from five different countries. It is the goal of this book to provide readers with an update on the molecular and cellular mechanisms of this biological process and hopefully to point out some new research directions for future therapeutic adventure.
| Author | : Elmer T. Skinard |
| Publisher | : Nova Publishers |
| Total Pages | : 180 |
| Release | : 2007 |
| Genre | : Medical |
| ISBN | : 9781600214738 |
Angiogenesis -- the growth of new blood vessels -- is an important natural process occurring in the body, both for health and as related to disease. Angiogenesis occurs in the healthy body to help heal wounds and to help to restore blood flow to tissues after injury or insult. In females, Angiogenesis also occurs during the monthly reproductive cycle (to rebuild the uterus lining, to mature the egg during ovulation) and during pregnancy (to build the placenta, the circulation between mother and foetus). The healthy body controls angiogenesis through a series of "on" and "off" switches. The main "on" switches are known as angiogenesis-stimulating growth factors. The main "off switches" are known as angiogenesis inhibitors. When angiogenic growth factors are produced in excess of angiogenesis inhibitors the balance is tipped in favour of blood vessel growth. When inhibitors are present in excess of stimulators, angiogenesis is stopped. The normal, healthy body maintains a perfect balance of angiogenesis modulators. In general, angiogenesis is "turned off" by the production of more inhibitors than stimulators. Tumour angiogenesis is the proliferation of a network of blood vessels that penetrates into cancerous growths, supplying nutrients and oxygen and removing waste products. Tumour angiogenesis actually starts with cancerous tumour cells releasing molecules that send signals to surrounding normal host tissue. This signalling activates certain genes in the host tissue that, in turn, cause proteins to encourage growth of new blood vessels. This book examines its angiogenesis within the context of theory and its applications to cancer treatment.
| Author | : I.D. Goldberg |
| Publisher | : Birkhäuser |
| Total Pages | : 437 |
| Release | : 2013-03-12 |
| Genre | : Science |
| ISBN | : 3034890060 |
We now know that excessive angiogenesis contributes to the development of a variety of disease processes, including cancer, chronic inflammatory disease, and diabetic retinopathy. On the other hand, insufficient angiogenesis may impair wound healing and organ repair. This volume describes recent advances in understanding the molecular regulation of angiogenesis. Subjects covered include important pro-angiogenic growth factors (e.g., vascular endothelial growth factor/vascular permeability factor, scatter factor/hepatocyte growth factor) and their receptors; angiogenesis inhibitors (e.g., thrombospondin-1, angiostatin); extracellular matrix factors (e.g., laminin) and specific vascular integrins (avb3 and avb5) that regulate angiogenesis; the roles of fibrin and the fibrinolytic system in angiogenesis; physical factors that regulate angiogenesis (hypoxia, pH); mechanisms by which specific cell types (macrophages, pericytes) regulate angiogenesis; and lymphangiogenesis, a subject often ignored in volumes of this type. Several chapters are also devoted to the prognostic and therapeutic implications of tumor angiogenesis, a subject of great interest to clinicians. Reflecting the latest advances in this exciting and expanding field, this comprehensive and authoritative monograph will prove invaluable to cell biologists, cancer researchers and pharmacologists.
| Author | : Thomas H. Adair |
| Publisher | : Morgan & Claypool Publishers |
| Total Pages | : 85 |
| Release | : 2011 |
| Genre | : Medical |
| ISBN | : 1615043306 |
Angiogenesis is the growth of blood vessels from the existing vasculature. The field of angiogenesis has grown enormously in the past 30 years, with only 40 papers published in 1980 and nearly 6000 in 2010. Why has there been this explosive growth in angiogenesis research? Angiogenic therapies provide a potential to conquer cancer, heart diseases, and more than 70 of life's most threatening medical conditions. The lives of at least 1 billion people worldwide could be improved with angiogenic therapy, according to the Angiogenesis Foundation. In this little book, we provide a simple approach to understand the essential elements of the angiogenic process, we critique the most powerful angiogenesis assays that are used to discover proangiogenic and antiangiogenic substances, and we provide an in-depth physiological perspective on how angiogenesis is regulated in normal, healthy tissues of the human body. All tissues of the body require a continuous supply of oxygen to burn metabolic substrates that are needed for energy. Oxygen is conducted to these tissues by blood capillaries: more capillaries can improve tissue oxygenation and thus enhance energy production; fewer capillaries can lead to hypoxia and even anoxia in the tissues. This means that angiogenic therapies designed to control the growth and regression of blood capillaries can be used to improve the survival of poorly perfused tissues that are essential to the body (heart, brain, skeletal muscle, etc.) and to rid the body of unwanted tissues (tumors). Table of Contents: Overview of Angiogenesis / Angiogenesis Assays / Regulation: Metabolic Factors / Regulation: Mechanical Factors / Glossary / References / Author Biographies
| Author | : Matthias Clauss |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 320 |
| Release | : 2006-01-17 |
| Genre | : Medical |
| ISBN | : 3764373113 |
Is it advisable to go back from bedside to the bench? During the last decade, few topics encountered such a broad interest in bio- gy and medicine as angiogenesis. The amazing ability of the body to restore blood flow by induction of blood vessel growth as part of an adaptive process has alarmed physicians dealing with diseases in which angiogenesis is either exaggerated (as in tumors) or too slow (as in ischemic diseases of heart and brain). Not surprisingly, pro- and antiangiogenic strategies have found their way into clinical trials. For instance, for the USA, the NIH website in early 2004 displayed 38 clinical studies involving either pro- or antiangiogenic th- apies. Given the expected overwhelming wealth of clinical data, the question may be asked whether further exploration of biological mechanisms is required or whether results from the bedside are instructive enough to proceed. This question depends also on the progress of pro- and antiangiogenic clinical trials. In the following, I give a short overview about some of the progress that has been made in this field. Since Judah Folkman proposed antiangiogenic tumor therapy thirty years ago, it has become increasingly evident that agents which interfere with blood vessel formation also block tumor progression. Accordingly, antiangiogenic therapy has gained much attention as a potential adjunct to conventional c- cer therapy.
